Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-cash Items (2021 - 2025)

Historic Non-cash Items for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $59.8 million.

  • ARS Pharmaceuticals' Non-cash Items fell 5540.31% to $59.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.8 million, marking a year-over-year decrease of 5540.31%. This contributed to the annual value of $71.5 million for FY2024, which is 18509.85% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Non-cash Items stood at $59.8 million for Q3 2025, which was down 5540.31% from $174.5 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Non-cash Items' 5-year high stood at $39.4 billion during Q1 2023, with a 5-year trough of $25.1 million in Q4 2023.
  • Its 5-year average for Non-cash Items is $5.9 billion, with a median of $74.5 million in 2024.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Non-cash Items soared by 8628030.32% in 2023, and later crashed by 9986.37% in 2024.
  • Quarter analysis of 5 years shows ARS Pharmaceuticals' Non-cash Items stood at $11.4 billion in 2021, then plummeted by 99.47% to $60.4 million in 2022, then tumbled by 58.51% to $25.1 million in 2023, then surged by 185.1% to $71.5 million in 2024, then dropped by 16.33% to $59.8 million in 2025.
  • Its Non-cash Items stands at $59.8 million for Q3 2025, versus $174.5 million for Q2 2025 and $101.1 million for Q1 2025.